Strontium malonate

Drug Profile

Strontium malonate

Alternative Names: NB S101; NSB-101

Latest Information Update: 23 Jul 2015

Price : $50

At a glance

  • Originator Osteologix Inc
  • Class Heavy metals; Osteoporosis therapies
  • Mechanism of Action Bone resorption factor inhibitors; Osteogenesis stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Postmenopausal osteoporosis

Most Recent Events

  • 05 Aug 2011 Strontium malonate is available for licensing in USA as of 05 Aug 2011. http://www.osteologix.com
  • 03 Aug 2010 Strontium malonate licensed to Servier worldwide, except in the US
  • 17 Feb 2009 Osteologix holds meeting with the US FDA on the proposed development of strontium malonate for Osteoporosis
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top